Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction
肺移植受者外泌体表型以及原发性移植物功能障碍和急性肺同种异体移植物功能障碍的风险
基本信息
- 批准号:10426535
- 负责人:
- 金额:$ 44.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-05 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAmericanAntigensAreaBiological MarkersBloodCaliberCellsChronicClinicalClinical ResearchCollectionCytometryDataData CollectionDevelopmentDiseaseEventExhibitsEyeFred Hutchinson Cancer Research CenterFunctional disorderFutureGoalsImmuneImmune responseImmunosuppressionInfrastructureInvestigationKnowledgeLeadLipid BindingLungLung TransplantationLung diseasesMeasurementMeasuresMediatingMethodologyMichiganModificationNational Heart, Lung, and Blood InstituteNatural ImmunityOutcomePathogenesisPatient-Focused OutcomesPatientsPhenotypeProbabilityPrognostic MarkerProspective cohort studyProtocols documentationQuality of lifeRaman Spectrum AnalysisReportingResearchResearch DesignResearch PriorityRiskRisk EstimateRisk FactorsRoleSamplingSpecimenStatistical Data InterpretationStratificationTherapeutic InterventionThoracic Surgical ProceduresTransplant RecipientsTransplantationTransplantation ImmunologyUniversitiesValidationWashingtonWisconsinadaptive immunitybasebiobankcell typeclinical riskcohortexosomeextracellular vesiclesfollow-upgraft dysfunctionhigh riskimmunoregulationimprovedinnovationinsightlung allograftmortalitymortality risknew therapeutic targetnovelnovel therapeutic interventionoutcome predictionpost-transplantpredictive markerpredictive modelingrisk predictionrisk stratificationtargeted treatmenttoolvesicular release
项目摘要
ABSTRACT
Lung transplantation improves survival and quality-of-life for patients with end-stage lung disease. Primary graft
dysfunction (PGD) and acute lung allograft dysfunction (ALAD) are early and intermediate events, respectively,
that threaten the long-term benefits of transplantation and increase the chances of chronic lung allograft
dysfunction (CLAD)—the primary cause of long-term mortality among lung transplant recipients. Efforts to
improve patient outcomes have relied, in part, on the use of risk-stratification to guide clinical decisions in lung
transplantation. Specifically, the Lung Allocation Score (LAS) ranks transplant candidates based on the risk of
death within one year of being listed and the probability of survival one year after transplantation. The estimated
risk of PGD and ALAD may present additional opportunities for stratification. However, in order to predict PGD
or ALAD accurately, recipient and donor risk factors exhibiting a strong association with these outcomes must
be identified. Most clinical risk factors do not have sufficiently strong associations with PGD or ALAD to facilitate
improvements in prediction outcomes. Biomarkers with a mechanistic role in the pathogenesis of PGD or ALD
are likely to be the strongest predictors of these outcomes. Notably, a growing body of evidence shows that
exosomes—30-150nm diameter lipid bound extracellular vesicles—released from immune and non-immune
cells—modulate the immune response to antigens in a variety of diseases. Our team recently proposed a
conceptual framework for the role of exosomes in innate and adaptive immunity that predicts the development
of PGD, ALAD, and CLAD. We recently demonstrated the feasibility of measuring recipient-derived exosomes
in patients with end-stage lung diseases and preliminary data suggest an association between exosome
phenotypes and CLAD. However, it remains to be determined whether recipient-derived exosome phenotypes
are associated with PGD or ALAD, whether changes in exosome phenotype occur post-transplant and if so,
whether these changes increase the risk of ALAD. To address these knowledge gaps, we propose a three-year
prospective cohort study with one-year follow-up of lung transplant recipients with the following aims: 1)
Determine if recipient-derived exosome phenotypes are associated with PGD, 2) Determine if recipient-derived
exosome phenotypes are associated with ALAD, and 3) Determine if PGD alters exosome phenotype post-
transplant and/or the risk of ALAD. The ultimate goal of our research is to improve patient outcomes by
increasing knowledge of biomarkers that predict PGD and ALAD. Evidence of an association between recipient-
derived exosome phenotypes and PGD and ALAD accomplishes the first step of developing a risk-stratification
tool to better inform transplant recipient selection and donor matching, and to further guide immunosuppression
and other post-transplant management protocols. This line of investigation is also expected to enhance our
knowledge of exosome-mediated immunoregulation, providing novel insights into the role of exosomes in the
pathogenesis of PGD and ALAD and novel therapeutic targets for future investigation.
抽象的
肺移植可改善终末期肺部疾病患者的生存和生活质量。主要移植
功能障碍(PGD)和急性肺同种异体功能障碍(ALAD)分别是早期和中间事件
这威胁着移植的长期益处并增加了慢性肺同种异体移植的机会
功能障碍(外壳) - 肺移植受者长期死亡率的主要原因。努力
改善患者预后,部分原因是使用风险分层来指导肺部的临床决策
移植。具体而言,肺分配评分(LAS)根据
在被列出的一年内死亡以及移植后一年生存的可能性。估计
PGD和Alad的风险可能会带来更多分层的机会。但是,为了预测PGD
或Alad准确地说,接受者和供体风险因素与这些结果有很强的联系
被识别。大多数临床风险因素与PGD或ALAD没有足够的牢固关联来促进
预测结果的改善。在PGD或ALD的发病机理中具有机械作用的生物标志物
可能是这些结果的有力预测指标。值得注意的是,越来越多的证据表明
外泌体 - 直径为30-150nm的脂质结合细胞外蔬菜 - 从免疫和非免疫中解释
细胞 - 调节多种疾病中对抗原的免疫反应。我们的团队最近提出了一个
外泌体在先天和适应性免疫中的作用的概念框架预测发展
PGD,Alad和clad。我们最近证明了测量受体衍生的外泌体的可行性
在末期肺部疾病和初步数据的患者中,外泌体之间存在关联
表型和外壳。但是,是否有待确定接受者衍生的外泌体表型
与PGD或ALAD相关,移植后外泌体表型的变化以及如果是这样,则
这些变化是否增加了阿拉德的风险。为了解决这些知识差距,我们提出了三年
前瞻性队列研究对肺移植受者进行了一年的随访,其目的是:1)
确定接受者衍生的外泌体表型是否与PGD相关联,2)确定接受者是否衍生
外泌体表型与Alad相关,3)确定PGD是否改变了外泌体表型。
移植和/或阿拉德的风险。我们研究的最终目的是通过
对预测PGD和ALAD的生物标志物的了解越来越多。接受者之间有关联的证据 -
派生的外泌体表型和PGD和ALAD完成了开发风险分层的第一步
更好地告知移植受者选择和捐助者匹配的工具,并进一步指导免疫抑制
和其他移植后管理方案。预计这一投资也将增强我们的
对外泌体介导的免疫调节的了解,为外泌体在
PGD和ALAD的发病机理以及新的治疗靶标,用于未来的研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Farhood Farjah其他文献
Farhood Farjah的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Farhood Farjah', 18)}}的其他基金
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction
肺移植受体外泌体表型以及原发性移植物功能障碍和急性肺同种异体移植物功能障碍的风险
- 批准号:
10677741 - 财政年份:2022
- 资助金额:
$ 44.99万 - 项目类别:
Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging
治疗前肺癌淋巴结分期的比较有效性
- 批准号:
10551866 - 财政年份:2022
- 资助金额:
$ 44.99万 - 项目类别:
Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging
治疗前肺癌淋巴结分期的比较有效性
- 批准号:
10365806 - 财政年份:2022
- 资助金额:
$ 44.99万 - 项目类别:
A Population-Based Analysis of Mediastinal Staging for Non-Small Cell Lung Cancer
非小细胞肺癌纵隔分期的人群分析
- 批准号:
7329894 - 财政年份:2007
- 资助金额:
$ 44.99万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Developing Real-world Understanding of Medical Music therapy using the Electronic Health Record (DRUMMER)
使用电子健康记录 (DRUMMER) 培养对医学音乐治疗的真实理解
- 批准号:
10748859 - 财政年份:2024
- 资助金额:
$ 44.99万 - 项目类别:
Identification of gene variants mediating the behavioral and physiological response to THC
鉴定介导 THC 行为和生理反应的基因变异
- 批准号:
10660808 - 财政年份:2023
- 资助金额:
$ 44.99万 - 项目类别:
Meeting the Challenges of COVID-19 by Expanding the Reach of Palliative Care: Proactive Advance Care Planning with Videos for the Elderly and all Patients with Dementia
通过扩大姑息治疗的范围来应对 COVID-19 的挑战:为老年人和所有痴呆症患者提供视频的主动预先护理计划
- 批准号:
10784057 - 财政年份:2023
- 资助金额:
$ 44.99万 - 项目类别:
Soft wireless multimodal cardiac implantable devices for long-term investigating heart failure pathogenesis
用于长期研究心力衰竭发病机制的软无线多模式心脏植入装置
- 批准号:
10735395 - 财政年份:2023
- 资助金额:
$ 44.99万 - 项目类别: